Immune-evasive beta cells in type 1 diabetes: innovations in genetic engineering, biomaterials, and computational modeling
Иммунно-уклоняющиеся бета-клетки при сахарном диабете 1-го типа: инновации в области генной инженерии, биоматериалов и компьютерного моделирования
2025-08-19
SCID: 54.1/jupmbecd
Discuss with AI
CRISPR/Cas9 gene editingbiomaterial encapsulationimmune-evasive beta cellsmachine learningtype 1 diabetes
Figures from the paper
Abstract (AI)
Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, resulting in lifelong insulin therapy that falls short of a true cure. Beta cell replacement therapies hold immense potential to restore natural insulin production, but they face significant hurdles such as immune rejection, limited donor availability, and long-term graft survival. In this review, we explore cutting-edge advances in genetic engineering, biomaterials, and machine learning approaches designed to overcome these barriers and enhance the clinical applicability of beta cell therapies. We highlight recent innovations in genetic editing techniques, particularly CRISPR/Cas9-based strategies, aimed at generating hypoimmune beta cells capable of evading immune detection. Additionally, we discuss novel biomaterial encapsulation systems, engineered at nano-, micro-, and macro-scales, which provide physical and biochemical protection, promote graft integration, and survival. We mention that recent advances in machine learning and computational modeling also play a crucial role in optimizing therapeutic outcomes, predicting clinical responses, and facilitating personalized treatment approaches. We also critically evaluate ongoing clinical trials, providing insights into the current translational landscape and highlighting both successes and remaining challenges. Finally, we propose future directions, emphasizing integrated approaches that combine genetic, biomaterial, and computational innovations to achieve durable, scalable, and immunologically tolerant beta cell replacement therapies for T1D.
Key Findings
1
Beta cell replacement could restore natural insulin production in T1D, but immune rejection, limited donors, and poor long-term graft survival remain major barriers.
2
CRISPR/Cas9-based genetic engineering is being used to generate hypoimmune beta cells designed to evade immune detection.
3
Clinical translation shows both progress and persistent challenges; integrated genetic, biomaterial, and computational approaches are proposed to achieve durable, scalable, immunologically tolerant therapies.
4
Machine learning and computational modeling can optimize therapeutic outcomes, predict clinical responses, and support personalized beta cell replacement strategies.
5
Nano-, micro-, and macro-scale biomaterial encapsulation systems provide physical and biochemical protection while promoting graft integration and survival.
Research Object
beta cell replacement therapies for type 1 diabetes, including engineered hypoimmune pancreatic beta cells and their biomaterial-encapsulated grafts
Research Subject
strategies and innovations for immune evasion, graft protection and integration, long-term survival, and clinical optimization of beta cell replacement therapies
Publication Details
Publication Date
2025-08-19
Journal
Frontiers in Immunology
Publisher
Frontiers Media
ISSN
1664-3224
Cited by
18
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Meal Simulation Model of the Glucose-Insulin System2007
Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques2023
In Silico Preclinical Trials: Methodology and Engineering Guide to Closed-Loop Control in Type 1 Diabetes Mellitus2009
Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes2024